Volastra Therapeutics
PrivateLast Round
Series B
Sep 23, 2025
Total Funding Raised
$166.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Volastra Therapeutics is a biotechnology company that develops oncology therapeutics targeting chromosomal instability to treat metastatic cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Volastra Therapeutics Comparables
Compare Volastra Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Simcere Pharmaceutical Group | 76% | |
| Apeiron Therapeutics | 74% | |
| China National Machinery Industry Corporation | 74% |
Volastra Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 23, 2025 | ||||
| Series A | Mar 7, 2023 | ||||
| Seed | Apr 6, 2021 | ||||
| Seed | Feb 11, 2020 |
Key People
Founding team and executive leadership
Volastra Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| B Capital Group | Series B |
| ARCH Venture Partners | Seed, Series A |
| Vida Ventures | Seed, Series A |
| Droia Ventures | Seed, Series A |
| Catalio Capital Management | Seed, Series A |
| ARCH Venture Partners | Seed, Series A |
| Cornell University Office of University Investments | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 78% MoM, reaching 4K.
- May 31, 2026
Two assets, VLS-1488 and Sovilnesib, granted designation by the FDA.
Volastra Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Volastra Therapeutics's valuation, stock price, and market status.
Is Volastra Therapeutics a public or private company?
Volastra Therapeutics is a private company.
What is the current stock price of Volastra Therapeutics?
Volastra Therapeutics is a private company, so its shares have no public market price. Caplight tracks Volastra Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Volastra Therapeutics worth (valuation)?
Valuation information for Volastra Therapeutics is not publicly available.
Can I buy Volastra Therapeutics stock?
Volastra Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Volastra Therapeutics's last funding round?
Volastra Therapeutics's most recent funding round was Series B on September 23, 2025.
Who are the main investors in Volastra Therapeutics?
Key investors in Volastra Therapeutics include ARCH Venture Partners, Vida Ventures, Catalio Capital Management, ARCH Venture Partners, Polaris Partners.
Will Volastra Therapeutics IPO soon?
No public IPO plans have been announced for Volastra Therapeutics.
How can I track Volastra Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Volastra Therapeutics's shares on secondary markets.